The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.

The FTC has taken unconstitutional actions in publishing a report that ignores the evidence provided by our company and other [pharmacy benefit managers], demonstrates clear ideological bias and advances a false and damaging narrative—narrative that could harm the health care system by removing essential checks and balances which would result in higher drug prices for American consumers,